AbbVie Inc. (ABBV)
PCE Inflation Increased In Line With Expectation
Today's pre-market activity is positive, with futures in the green across major indexes: the Dow is +110 points at this hour, with the S&P 500 +26 and the Nasdaq leading the way, +158 points. The small-cap Russell 2000 is +5.
December PCE Steady with Expectations; Plenty of Mixed Q4 Earnings
PCE results were as in-line with expectations as one could expect: +0.3% on headline month over month, +2.6% year over year.
AbbVie shares rise as new drug sales offset Humira decline in Q4
Abbvie Inc (NYSE:ABBV) shares surged after the company posted a positive financial report for the fourth quarter, with sales growth of newer drugs offsetting a steep decline in Humira revenue. Earnings per share of $2.16 topped estimates of $2.13, but marked a decline from $2.79 in the year-ago quarter.
AbbVie Investors Trigger Trend-Following Signal: Time to Load Up
AbbVie NYSE: ABBV is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira's patent cliff are behind it, with Skyrizi, Rinvoq, and the diversified portfolio of products gaining traction.
AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook
AbbVie (ABBV) stock was one of the top gainers in the S&P 500 Friday morning as the biotech firm posted better-than-expected sales and gave strong guidance on higher demand for two of its drugs to treat inflammation.
Compared to Estimates, AbbVie (ABBV) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for AbbVie (ABBV) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.16 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $2.79 per share a year ago.
AbbVie's newer immunology drugs are offsetting Humira's decline, sending stock up 4%
AbbVie's earnings topped estimates as it offered an upbeat view of 2025.
AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug that now faces stiff competition.
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
As AbbVie Inc. ABBV and Novartis AG NVS prepare to report their fourth-quarter earnings before market open on Friday, investors are eyeing the technical setups of both pharmaceutical giants.
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?
Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems from a fundamental truth: A sustainable high dividend yield often serves as a powerful indicator of intrinsic value.
